Clinical Trials Logo

Filter by:
NCT ID: NCT03916692 Terminated - Glycemic Index Clinical Trials

GRAPE • Glycemic Response of Amylopectin Containing Drinks

GRAPE
Start date: April 23, 2019
Phase: N/A
Study type: Interventional

To quantify the glycemic index of the SP energy-smart-based nutrition supplement and the SP Glucose-support formula as compared to a glucose drink. We hypothesized that both the energy-smart-based nutritional supplement and the SP Glucose-support formula will have low glycemic index. The aim of the study is to quantify the glycemic index of the SP energy-smart-based nutrition supplement and the SP Glucose-support formula as compared to a glucose drink. We hypothesized that both the energy-smart-based nutritional supplement and the SP Glucose-support formula will have low glycemic index.

NCT ID: NCT03916588 Terminated - Dementia Clinical Trials

Dementia Management With Interactive Technology

Start date: August 16, 2018
Phase:
Study type: Observational

To investigate the efficacy of an individualized treatment plan delivered through remote technology along with enhanced staff training within a supervised memory unit on patient outcome, care quality, health care utilization/cost, and staff burden. Remote monitoring of activity data will also be explored.

NCT ID: NCT03916068 Terminated - Breast Cancer Clinical Trials

Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This study aims to compare patients that receive hyperbaric oxygen or Trental and Vitamin E immediately after completion of radiation therapy to evaluate which treatment best reduces radiation fibrosis.

NCT ID: NCT03915405 Terminated - Clinical trials for Urothelial Carcinoma

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Start date: September 26, 2019
Phase: Phase 1
Study type: Interventional

This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).

NCT ID: NCT03914989 Terminated - Cognitive Function Clinical Trials

Sensory Enrichment for Older Adults

Start date: March 8, 2019
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of multi-odorant enrichment on cognitive skills, olfactory function, and quality of life.

NCT ID: NCT03914495 Terminated - NAFLD Clinical Trials

The Role of Microbiome Reprogramming on Liver Fat Accumulation

MILE
Start date: May 21, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.

NCT ID: NCT03913702 Terminated - Clinical trials for Subacromial Impingement Syndrome

Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement

Start date: September 9, 2019
Phase: Phase 2
Study type: Interventional

The investigators aim to compare subacromial ketorolac (non-steroidal anti-inflammatory drug) versus methylprednisolone (steroid) for the treatment of shoulder impingement syndrome.

NCT ID: NCT03913676 Terminated - Anxiety Clinical Trials

Disseminating a Waitlist Treatment for Anxiety With Velibra

Start date: November 5, 2019
Phase: N/A
Study type: Interventional

Cognitive Behavioral Therapy (CBT) is a gold standard treatment for a wide spectrum of anxiety-related concerns. However, long waitlist times can serve as a substantial barrier to those seeking treatment. Internet delivered psychotherapy, such as internet-based CBT (I-CBT) may present an affordable option for disseminating empirically supported treatments. Velibra, an web-based I-CBT intervention, has shown initial promise in treating anxiety disorders. Velibra has been used to treat anxiety-related disorders in European samples with participants recruited from general practitioner's offices and diagnosed with a specific subset of anxiety disorders. While these effects are encouraging, additional research is needed toevaluate whether Velibra could be implemented in a community mental health clinic in the U.S. Specifically, if Velibra could be successfully implemented within the context of mental health clinic waitlists, it may be capable of providing evidence-based treatment to larger groups of people at a faster rate than mental health clinics can structurally support. The purpose of this study is to assess the feasibility of implementing Velibra into an American community clinic waitlist. We plan to offer free access to the Velibra program to members of the Anxiety and Stress Clinic (ASC) waitlist at the University of Texas at Austin experiencing anxiety. We will evaluate interest in the program, user data from the program, and opinions of the program post-completion. We hypothesize ASC patients will find utility in Velibra's ability to offer them mental health resources faster than the traditional waitlist can provide.

NCT ID: NCT03913130 Terminated - Eye Diseases Clinical Trials

Extension Study to Study PQ-110-001 (NCT03140969)

INSIGHT
Start date: May 13, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.

NCT ID: NCT03912831 Terminated - Clinical trials for Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Start date: April 30, 2019
Phase: Phase 1
Study type: Interventional

This study has 2 parts: Phase 1A and Phase 1B. The primary objectives of Phase 1A are to evaluate the safety of KITE-439 and to determine a recommended Phase 1B dose. The primary objective of Phase 1B is to estimate the efficacy of KITE-439 in adults who are human leukocyte antigen (HLA)-A*02:01+ and have relapsed/refractory human papillomavirus (HPV)16+ cancers.